enVVeno Medical Corporation (NASDAQ:NVNO - Get Free Report) Director Robert Gray purchased 3,500 shares of the firm's stock in a transaction dated Tuesday, December 31st. The shares were bought at an average price of $2.94 per share, with a total value of $10,290.00. Following the purchase, the director now owns 11,155 shares in the company, valued at $32,795.70. This represents a 45.72 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
enVVeno Medical Stock Performance
NVNO opened at $3.07 on Friday. The firm has a market cap of $53.85 million, a P/E ratio of -2.38 and a beta of 1.22. The business has a 50 day moving average price of $3.16 and a 200 day moving average price of $4.25. enVVeno Medical Corporation has a twelve month low of $2.45 and a twelve month high of $6.97.
enVVeno Medical (NASDAQ:NVNO - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.02). As a group, analysts anticipate that enVVeno Medical Corporation will post -1.3 earnings per share for the current fiscal year.
Institutional Investors Weigh In On enVVeno Medical
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
From Brownstone Research | Ad
Elon Musk believes his new AI product will be worth an incredible $9 trillion.
But the mainstream media is not buying it.
Click here to watch this demo and decide for yourself.
A number of hedge funds have recently bought and sold shares of the company. Corsair Capital Management L.P. acquired a new position in shares of enVVeno Medical during the 3rd quarter worth about $390,000. Maven Securities LTD acquired a new position in shares of enVVeno Medical during the third quarter worth approximately $295,000. Hohimer Wealth Management LLC bought a new stake in shares of enVVeno Medical in the third quarter valued at approximately $286,000. Westside Investment Management Inc. grew its stake in shares of enVVeno Medical by 128.0% in the third quarter. Westside Investment Management Inc. now owns 88,375 shares of the company's stock worth $297,000 after acquiring an additional 49,613 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in enVVeno Medical by 7.8% during the third quarter. Geode Capital Management LLC now owns 150,676 shares of the company's stock worth $506,000 after acquiring an additional 10,902 shares during the period. 34.71% of the stock is currently owned by institutional investors.
About enVVeno Medical
(
Get Free Report)
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
